Filings & corporate actions
41 results filed
CSVNext results · Q2 FY27
Expected 20 Oct 2026 – 28 Oct 2026
Estimate: filed 20–28 days after quarter end, last 5 times
Dividend
₹1.20 per share · last 8 May 2026
2026
- 24 JulresultsResults · Q1 FY27 · consolidated and standalone+7.0%NSE
- 21 JulshareholdingShareholding · 30 Jun 2026+2.2%NSE
- 8 MaydividendDividend · ₹1.20 per share+1.8%
- 30 AprresultsResults · Q4 FY26 · consolidated and standalone+5.9%NSE
- 20 AprshareholdingShareholding · 31 Mar 2026-0.6%NSE
- 23 JanresultsResults · Q3 FY26 · consolidated and standalone-1.6%NSE
- 21 JanshareholdingShareholding · 31 Dec 2025-4.6%NSE
Reaction to results · all yearsrose on day 0 in 20 of 43 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 24 Jul 2026 | +7.0% | +13.1% | +12.5% | 3.3× |
| Q4 FY26 | 30 Apr 2026 | +5.9% | +15.1% | +25.6% | 2.7× |
| Q3 FY26 | 23 Jan 2026 | -1.6% | -6.1% | +0.1% | 2.6× |
| Q2 FY26 | 23 Oct 2025 | -0.9% | +2.1% | +4.8% | 4.0× |
| Q1 FY26 | 25 Jul 2025 | +6.1% | +2.8% | +3.7% | 6.9× |
| Q4 FY25 | 25 Apr 2025 | -3.1% | -4.3% | -7.8% | 2.8× |
| Q3 FY25 | 24 Jan 2025 | -11.3% | -1.2% | -13.5% | 11.1× |
| Q2 FY25 | 24 Oct 2024 | +4.1% | +11.7% | +22.1% | 9.7× |
| Q1 FY25 | 25 Jul 2024 | +3.5% | +3.1% | +3.2% | 2.4× |
| Q4 FY24 | 25 Apr 2024 | +2.6% | +3.1% | +3.6% | 3.0× |
| Q3 FY24 | 24 Jan 2024 | -5.5% | -2.1% | -0.6% | 14.6× |
| Q2 FY24 | 20 Oct 2023 | -9.6% | -9.8% | -6.8% | 8.5× |
| Q1 FY24 | 27 Jul 2023 | -1.8% | +14.1% | +13.8% | 4.3× |
| Q4 FY23 | 27 Apr 2023 | +5.3% | +13.0% | +14.6% | 4.8× |
| Q3 FY23 | 30 Jan 2023 | 0.0% | -2.3% | -7.8% | 2.8× |
| Q2 FY23 | 21 Oct 2022 | -1.3% | -3.2% | -6.2% | 0.9× |
| Q1 FY23 | 27 Jul 2022 | +2.2% | +5.8% | +12.2% | 5.1× |
| Q4 FY22 | 28 Apr 2022 | +2.0% | -5.1% | -0.8% | 2.6× |
| Q3 FY22 | 27 Jan 2022 | +7.6% | +13.8% | +14.3% | 4.4× |
| Q2 FY22 | 28 Oct 2021 | -4.2% | -7.7% | -5.6% | 2.6× |
| Q1 FY22 | 29 Jul 2021 | +6.0% | +12.3% | +7.2% | 3.2× |
| Q4 FY21 | 29 Apr 2021 | -1.2% | +6.4% | +14.3% | 1.2× |
| Q3 FY21 | 28 Jan 2021 | -3.6% | -4.6% | -2.3% | 1.8× |
| Q2 FY21 | 29 Oct 2020 | -3.2% | -16.1% | -2.1% | 2.4× |
| Q1 FY21 | 30 Jul 2020 | +18.1% | +29.4% | +47.2% | 6.7× |
| Q4 FY20 | 30 Apr 2020 | -4.4% | -16.2% | -8.9% | 4.5× |
| Q3 FY20 | 30 Jan 2020 | -1.3% | +0.7% | -4.5% | 9.7× |
| Q2 FY20 | 31 Oct 2019 | +2.3% | -1.0% | -7.4% | 24.9× |
| Q1 FY20 | 3 Aug 2019 | -5.0% | +0.2% | -0.5% | 5.1× |
| Q4 FY19 | 9 May 2019 | +0.7% | -2.8% | -8.9% | 0.2× |
| Q3 FY19 | 6 Feb 2019 | -1.1% | -4.6% | +0.2% | 0.2× |
| Q2 FY19 | 22 Nov 2018 | -2.3% | +0.4% | -2.0% | 0.2× |
| Q4 FY18 | 6 Sept 2018 | +0.6% | +2.8% | -6.8% | 0.2× |
| Q1 FY19 | 20 Aug 2018 | -0.2% | -0.2% | -1.8% | 0.3× |
| Q4 FY16 | 2 Apr 2018 | +0.9% | -0.3% | -0.9% | 0.6× |
| Q3 FY18 | 2 Feb 2018 | -1.5% | -0.6% | +3.6% | 0.9× |
| Q2 FY17 | 16 Nov 2017 | +0.4% | +2.0% | -0.6% | 0.3× |
| Q2 FY18 | 16 Nov 2017 | +0.4% | +2.0% | -0.6% | 0.3× |
| Q1 FY18 | 21 Aug 2017 | -1.2% | -1.1% | +4.3% | 0.9× |
| Q1 FY17 | 21 Aug 2017 | -1.2% | -1.1% | +4.3% | 0.9× |
| Q4 FY17 | 12 Jun 2017 | 0.0% | -2.5% | -3.7% | 0.7× |
| Q3 FY16 | 17 Feb 2017 | +0.9% | +1.8% | +2.3% | 1.2× |
| Q3 FY17 | 17 Feb 2017 | +0.9% | +1.8% | +2.3% | 1.2× |
| Average | +0.3% | +1.5% | +2.7% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+29.1%
Profit YoY+123.9%
Interest cost YoY—
Revenue QoQ+11.9%
Profit QoQ+28.4%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen1,968.90
Day range1,958.00 – 2,054.90
52-week range826.20 – 2,055.30
From 52w high-0.3%
RSI (14)66.1
ATR (14)51.62
Volume21.97L
Avg volume (20D)17.40L
Rel volume1.26×
Volatility (1Y)29.0%
Turnover₹450.4Cr
SMA 50 / 2001,890.44 / 1,363.02
Delivery percentage
Latest · 6 Oct 202657.8%
20-day avg51.7%
1-year avg50.6%
Percentile (own history)86th
Range9.5–96.5%
Sessions1,731
Over the last 20 sessions LAURUSLABS settled 51.7% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 50.6%. The latest session ranks higher than 86% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +3.99% | +1.95% | +9.71% | +38.76% | +96.57% | +146.31% |
Valuation
CSVMarket cap₹1.11L Cr
P/E (TTM)88.5
EPS (TTM)23.18
Shares outstanding54.02Cr
Listed19 Dec 2016
Ownership
CSVPromoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 1,653.5 | 1,778.3 | 1,811.6 | 2,026.3 |
| YoY chg | — | — | +5.3% | +29.1% |
| Net profit (₹ Cr) | 194.5 | 251.9 | 282.1 | 362.1 |
| YoY chg | — | — | +21.2% | +123.9% |
| Net margin | 11.8% | 14.2% | 15.6% | 17.9% |
| EPS | 3.61 | 4.65 | 5.17 | 6.80 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 27.47% · public 72.53%2021-092026-06
- Promoter
- Public and others
- Promoter
- 27.47%
- Public
- 72.53%
- Promoter change
- -0.02 pp
- Filed
- 21 Jul 2026
- FII
- 28.00%
- DII
- 13.74%
- Promoter pledged
- 2.69%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26R | Q3 FY26 | Q4 FY26 | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,224.5 | 1,194.9 | 1,439.7 | 1,194.9 | 1,223.7 | 1,415.1 | 1,720.3 | 1,569.6 | 1,653.5 | 1,778.3 | 1,811.6 | 2,026.3 | |
| Other income | 1.8 | 2.4 | 18.5 | 2.5 | 4.6 | 9.4 | 58.6 | 10.4 | 27.0 | 5.8 | 11.8 | 9.2 | |
| Total income | 1,226.2 | 1,197.4 | 1,458.2 | 1,197.4 | 1,228.3 | 1,424.5 | 1,778.9 | 1,580.0 | 1,680.4 | 1,784.1 | 1,823.4 | 2,035.5 | |
| Total expenses | 1,172.3 | 1,162.7 | 1,350.9 | 1,179.0 | 1,205.5 | 1,293.8 | 1,466.5 | 1,355.8 | 1,410.7 | 1,457.5 | 1,462.0 | 1,554.1 | |
| └ Finance costs | 42.4 | 50.8 | 50.5 | 49.2 | 52.6 | 57.8 | 56.4 | 51.5 | 40.0 | 38.8 | 40.4 | 42.2 | |
| └ Depreciation | 93.4 | 98.4 | 102.3 | 106.1 | 107.5 | 106.1 | 110.4 | 116.8 | 120.5 | 120.6 | 122.1 | 123.9 | |
| Profit before tax | 53.9 | 34.6 | 107.3 | 18.5 | 22.8 | 130.7 | 312.3 | 224.2 | 269.7 | 326.6 | 361.4 | 481.4 | |
| Tax expense | 14.6 | 9.5 | 32.0 | 6.3 | 5.1 | 40.1 | 78.5 | 63.1 | 76.0 | 73.5 | 79.5 | 119.4 | |
| Net profit | 37.1 | 23.3 | 75.0 | 12.7 | 20.0 | 92.9 | 232.8 | 161.7 | 194.5 | 251.9 | 282.1 | 362.1 | |
| EPS | 0.69 | 0.43 | 1.40 | 0.23 | 0.37 | 1.71 | 4.34 | 3.02 | 3.61 | 4.67 | 5.17 | 6.81 | |
| Net margin | 3.03% | 1.95% | 5.21% | 1.06% | 1.63% | 6.57% | 13.53% | 10.30% | 11.76% | 14.16% | 15.57% | 17.87% | |
| PBT margin | 4.40% | 2.90% | 7.45% | 1.54% | 1.86% | 9.24% | 18.16% | 14.29% | 16.31% | 18.36% | 19.95% | 23.76% | |
| Tax rate | 27.04% | 27.30% | 29.78% | 33.86% | 22.31% | 30.66% | 25.12% | 28.16% | 28.17% | 22.49% | 21.99% | 24.80% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 24 Jul 2026.
LAURUSLABS at a glance
- LAURUSLABS closed at ₹2,050 on 6 Oct 2026, +3.99% on the day, +146.3% over one year, at its 52-week high of ₹2,055.3.
- Delivery was 57.8% of traded quantity on 6 Oct 2026, the 86th percentile of its own 1,731 sessions with a reading (20-session average 51.7%, 1-year average 50.6%).
- Market capitalisation is ₹1.11 lakh crore at a trailing P/E of 88.5 (trailing EPS ₹23.18).
- Q1 FY27 results (consolidated, filed 24 Jul 2026): revenue ₹2,026 crore (+29.1% year on year), net profit ₹362 crore (+123.9%); the price moved +7.0% on the first session after.
- Promoters held 27.47% at 30 Jun 2026, down 0.02 percentage points on the previous filing, with 2.69% of promoter shares pledged.
- Q2 FY27 results are expected between 20 Oct 2026 and 28 Oct 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE947Q01028
SeriesEQ
Listed19 Dec 2016
History from19 Dec 2016
Sessions2,425
Turnover rank#64
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
- MANKINDMankind Pharma Limited2,500.00+0.85%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE